Email the author Differences in C-Reactive Protein Level Based on Clinical Severity and Outcome of COVID-19 Patients at RSUP Dr. M. Djamil Padang
Abstract
Background: Inflammatory process in COVID-19 can increase inflammatory markers such as C-reactive protein (CRP), procalcitonin (PCT), and interleukin 6 (IL-6). The level of C-reactive protein describes the severity of viral infection. Several studies had been conducted to investigate the link between C-reactive protein level and the severity of COVID-19. The purpose of this study is to identify differences in C-reactive protein levels based on clinical degrees and outcomes of COVID-19 patients treated at RSUP by Dr. M. Jamil Padang.
Methods: This is a retrospective cohort study that analyzed all COVID-19 patients treated at RSUP Dr. M. Djamil Padang. This study lasted from December 1st, 2021 and June 1st, 2022. The data was analyzed using univariate, bivariate, and confounding analysis. Bivariate analysis explored differences in C-reactive protein levels in clinical severity and patient outcomes for COVID-19. The Kruskal-Wallis test determined the difference between the CRP level and clinical severity, while the Mann-Whitney test determined the difference between the CRP level and length of stay and final hospitalization status. Confounding test was performed using multiple linear regression tests.
Results: Majority of participants were women (51.0%) with range of age between 50–59 years (28.0%) and suffered from hypertension (46.0%). Less than half of them had secondary infection (49.0%). Majority of them had a critical clinical severity (75.0%) and length of stay ≤14 days (77.0%) and more than half were deceased (65.0%). C-reactive protein levels were higher in patients with critical clinical degrees (89.00 mg/L) compared to moderate (37.50 mg/L) and severe (23.00 mg/L), C-reactive protein levels in patients with long hospitalization ≤14 days (97.00 mg/L) was higher than >14 days (88.50 mg/L), and C-reactive protein levels were higher in patients who died (93.00 mg/L) than those who survived (68.00 mg/L).
Conclusion: C-reactive protein levels differed significantly based on clinical severity, length of stay and end of stay status of COVID-19 patients.
Keywords
Full Text:
PDFReferences
Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A, et al. The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol. 2021;50(2):420–9.
Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, et al. Association of elevated inflammatory markers and severe COVID-19: A meta-analysis. Medicine. 2020;99(47):e23315.
Liu F, Li L, Xu M Da, Wu J, Luo D, Zhu YS, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.
Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020;96:467–74.
Baumeister D, Akhtar R, Ciufolini S, Pariante CM, Mondelli V. Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-α. Mol Psychiatry. 2016;21(5):642–9.
Pepys MB. C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target? Eur Heart J. 2021;42(23):2280–3.
Li Q, Ding X, Xia G, Chen HG, Chen F, Geng Z, et al. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study. EClinicalMedicine. 2020;23:100375.
Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. 2020;92(7):856–62.
Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020;19(1):18.
Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42(23):2270–9.
Fortunato F, Martinelli D, Caputo S Lo, Santantonio T, Dattoli V, Lopalco PL, et al. Sex and gender differences in COVID-19: An Italian local register-based study. BMJ Open. 2021;11(10):e051506.
Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. Lancet Reg Health West Pac. 2021;9:100108.
Das SK. The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19). Indian Journal of Clinical Biochemistry. 2020;35(4):385–96.
Fresán U, Guevara M, Trobajo-Sanmartín C, Burgui C, Ezpeleta C, Castilla J. Hypertension and related comorbidities as potential risk Factors for COVID-19 hospitalization and severity: A prospective population-based cohort study. J Clin Med. 2021;10(6):1–12.
Mitra P, Suri S, Goyal T, Misra R, Singh K, Garg MK, et al. Association of comorbidities with coronavirus disease 2019: A review. Ann Natl Acad Med Sci. 2020;56(02):102–11.
Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O, et al. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PLoS One. 2021;16(3):e0248281.
Bae SA, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2021;107(5):373–80.
Corrao S, Pinelli K, Vacca M, Raspanti M, Argano C. Type 2 diabetes mellitus and COVID-19: A narrative review. Front Endocrinol (Lausanne). 2021;12:609470.
Hessami A, Shamshirian A, Heydari K, Pourali F, Alizadeh-Navaei R, Moosazadeh M, et al. Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. Am J Emerg Med. 2021;46:382–91.
Ciapponi A, Bardach A, Comandé D, Berrueta M, Argento FJ, Cairoli FR, et al. COVID-19 and pregnancy: An umbrella review of clinical presentation, vertical transmission, and maternal and perinatal outcomes. PLoS One. 2021;16(6):e0253974.
Callender LA, Curran M, Bates SM, Mairesse M, Weigandt J, Betts CJ. The impact of pre-existing comorbidities and therapeutic interventions on COVID-19. Front Immunol. 2020;11:1991.
Bakouny Z, Hawley JE, Choueiri TK, Peters S, Rini BI, Warner JL, et al. COVID-19 and cancer: Current challenges and perspectives. Cancer Cell. 2020;38(5):629–46.
Ng WH, Tipih T, Makoah NA, Vermeulen JG, Goedhals D, Sempa JB, et al. Comorbidities in SARS-CoV-2 patients: A systematic review and meta-analysis. mBio. 2021;12(1):e03647-20.
Samiullah SM, Surekha A, Devi AR, Nagajyothi B. Evaluation of the secondary bacterial infections of respiratory tract in COVID-19 patients. Indian J Med Microbiol. 2021;39:S69–70.
Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: A retrospective analysis. Antimicrob Resist Infect Control. 2020;9(1):1–7.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054–62.
Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, et al. Prognostic value of C-reactive protein in patients with coronavirus 2019. Clin Infect Dis. 2020;71(16):2174–9.
Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. International Journal of Infectious Diseases. 2020;95:304–7.
Acar E, Demir A, Yıldırım B, Kaya MG, Gökçek K. The role of hemogram parameters and C-reactive protein in predicting mortality in COVID-19 infection. Int J Clin Pract [Internet]. 2021 Jul 1 [cited 2023 Oct 23];75(7). Available from: https://pubmed.ncbi.nlm.nih.gov/33887100/
Danwang C, Endomba FT, Nkeck JR, Wouna DLA, Robert A, Noubiap JJ. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020;8:37.
Luan YY, Yin CH, Yao YM. Update advances on C-reactive protein in COVID-19 and other viral infections. Front Immunol. 2021;12:720363.
Tang Y, Liang P, Chen J, Fu S, Liu B, Feng M, et al. The baseline levels and risk factors for high-sensitive C-reactive protein in Chinese healthy population. Immun Ageing. 2018;15:21.
Kanmani S, Kwon M, Shin MK, Kim MK. Association of C-reactive protein with risk of developing type 2 diabetes mellitus, and role of obesity and hypertension: A large population-based Korean cohort study. Scientific Reports 2019 9:1. 2019;9(1):1–8.
Mei Z, Li H, Serdula MK, Flores-Ayala RC, Wang L, Liu JM, et al. C-reactive protein increases with gestational age during pregnancy among Chinese women. Am J Hum Biol. 2016;28(4):574–9.
Lentner J, Adams T, Knutson V, Zeien S, Abbas H, Moosavi R, et al. C-reactive protein levels associated with COVID-19 outcomes in the United States. Journal of osteopathic medicine. 2021;121(12):869–73.
Devran Ö, Karakurt Z, Adigüzel N, Güngör G, Moçin ÖY, Balci MK, et al. C-reactive protein as a predictor of mortality in patients affected with severe sepsis in intensive care unit. Multidiscip Respir Med. 2012;7(1):47.
Villoteau A, Asfar M, Otekpo M, Loison J, Gautier J, Annweiler C. Elevated C-reactive protein in early COVID-19 predicts worse survival among hospitalized geriatric patients. PLoS One. 2021;16(9):e0256931.
Bannaga AS, Tabuso M, Farrugia A, Chandrapalan S, Somal K, Lim VK, et al. C-reactive protein and albumin association with mortality of hospitalised SARS-CoV-2 patients: A tertiary hospital experience. Clin Med (Lond) [Internet]. 2020 [cited 2023 Oct 24];20(5):463–7. Available from: https://pubmed.ncbi.nlm.nih.gov/32934038/
Valerio L, Ferrazzi P, Sacco C, Ruf W, Kucher N, Konstantinides S V., et al. Course of D-dimer and C-reactive protein levels in survivors and nonsurvivors with COVID-19 pneumonia: A retrospective analysis of 577 patients. Thromb Haemost. 2021;121(1):98–101.
Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–4.
Tsivgoulis G, Katsanos AH, Ornello R, Sacco S. Ischemic stroke epidemiology during the COVID-19 pandemic: Navigating uncharted waters with changing tides. Stroke. 2020;51(7):1924–6.
DOI: https://doi.org/10.36497/jri.v43i4.427
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Isnaniyah Usman, Irvan Medison, Deddy Herman
INDEXING & PARTNER
| Jurnal Respirologi Indonesia pISSN: 0853-7704 - eISSN: 2620-3162 Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia Phone: +62-21-2247-4845 Email: editor@jurnalrespirologi.org |  An official publication by the Indonesian Society of Respirology (ISR) |
 Creative Commons Attribution-ShareAlike 4.0 International License Statcounter |